Lodosyn
(Carbidopa)ApprovedSmall molecule
Carbidopa is used together with levodopa to treat Parkinson's disease by helping more of the levodopa reach the brain where it can work better to reduce symptoms like tremors and stiffness.[2] Lodosyn is currently approved and in use across 31 indications[4].[1]
Lodosyn is one of 612 small molecule programs targeting Albinism. It is currently in Approved.
31
Indications
23
Total Trials
1
Active Trials
611
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 30 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Lodosyn
LLaTonya J. Hickson
Approved
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Spiriva
Boehringer IngelheimPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mobility3 trials
Idiopathic Parkinson's Disease2 trials
Parkinson's Disease2 trials
CAR2 trials
Single Dose1 trial
11 more indications
Multiple Sclerosis1 trial
Parkinsonism1 trial
Fibromyalgia1 trial
Cocaine Dependence1 trial
Familial dysautonomia1 trial
Asthma1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LODOSYN
NDA NDA017830
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lodosyn drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Carbidopa. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DOPA Decarboxylase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- LLaTonya J. Hickson